CClinicalTrials.gg
Not yet recruitingNCT07295860NILEUpdated Dec 26, 2025

FANS-FURS vs Suction Mini-PCNL for 2-3 cm Renal Stones: A Multicenter Randomized Trial

An interventional study of FANS-Based Flexible Ureteroscopy (FURS) and Suction-Assisted Mini-PCNL in Stone, Kidney and Stone, Urinary, sponsored by Mansoura University. Not yet recruiting at 9 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter, prospective, randomized clinical trial compares FANS-assisted flexible ureteroscopy (FURS) with suction-assisted mini-percutaneous nephrolithotomy (mini-PCNL) for the treatment of renal stones measuring 2-3 cm. A total of 280 patients will be enrolled across nine tertiary centers and randomized 1:1 to either technique. The primary endpoint is stone-free rate (SFR) at 1 month, assessed by non-contrast CT. Secondary outcomes include operative time, intraoperative complications, postoperative morbidity (Clavien-Dindo), pain scores, hospital stay, reinterventions, and quality of life (EQ-5D-5L). The study aims to provide the first high-quality head-to-head evidence comparing these two modern suction-enhanced technologies, with the goal of defining the optimal minimally invasive approach for medium-sized renal stones.

Read the detailed description

Aim of the Study

The primary aim of this study is to compare the stone-free rate (SFR) of FANS-assisted flexible ureteroscopy versus suction-assisted mini-percutaneous nephrolithotomy (mini-PCNL) in patients with renal stones measuring 2 to 3 cm. Secondary aims include comparing perioperative outcomes, complication rates, length of hospital stay, and patient-reported quality of life between the two treatment modalities.

Patients and Methods Study Design

This is a prospective, multicenter, randomized, superiority trial. Patients will be recruited from nine high-volume tertiary referral centers. Participants will be randomized in a 1:1ratio to undergo either FANS-based flexible ureteroscopy or suction mini-PCNL using a computer-generated randomization tables, stratified by each center. Allocation concealment will be maintained using sequentially numbered, opaque, sealed envelopes (SNOSE) prepared by an independent person who is not involved in patients' recruitment or treatment. Surgeons and investigators will be blinded to group allocation until the point of intervention.

Ethical Considerations The study protocol will be approved by the Institutional Review Board (IRB) of each participating center. All patients will provide written informed consent before enrollment. The study will be conducted in accordance with the principles of the Declaration of Helsinki.

Patient Evaluation and Recruitment All patients will undergo a standardized preoperative assessment including medical history, physical examination, blood tests (CBC, renal function, coagulation profile), urinalysis, urine culture, and non-contrast CT (NCCT) for stone size, density (HU), and volume assessment. Eligible patients will be screened and enrolled after providing informed consent. Antibiotic prophylaxis will be administered according to European Association of Urology (EAU) guidelines.

02

Conditions studied

  • Stone, Kidney
  • Stone, Urinary

Keywords

  • Renal stones
  • Nephrolithiasis
  • Urolithiasis
  • RIRS
  • FANS
  • mini-PCNL
  • Suction technology
  • Stone-free rate
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults ≥18 years old.
  • Single or multiple renal stones measuring 2 -3 cm (diagnosed by NCCT).
  • Negative urine culture prior to surgery.
  • Suitable for general/spinal anesthesia.
  • Signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Active urinary tract infection.
  • Anomalous renal anatomy (e.g., horseshoe kidney).
  • Severe ureteral strictures preventing retrograde access.
  • Coagulopathy or inability to discontinue anticoagulation.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
254 participants (estimated)

Study arms

  • Experimental
    FANS-Based Flexible Ureteroscopy (FURS)

    Procedure: FANS-Based Flexible Ureteroscopy (FURS)

  • Active comparator
    Suction-Assisted Mini-PCNL

    Procedure: Suction-Assisted Mini-PCNL

Interventions

  • ProcedureFANS-Based Flexible Ureteroscopy (FURS)

    Under general/ spinal anesthesia, patients will be placed in lithotomy position. After guidewire placement, a flexible navigable suction ureteral access sheath (FANS) will be advanced to the renal pelvis. Lithotripsy will be performed using a digital flexible ureteroscope and holmium laser with optimized settings for dusting and fragmentation. Continuous irrigation combined with active suction will enhance visualization and fragment clearance. A double-J stent will be placed post-procedure.

  • ProcedureSuction-Assisted Mini-PCNL

    Under general or spinal anesthesia, patients will be placed in the prone position. Percutaneous renal access will be achieved under ultrasound or fluoroscopy guidance using an 18G puncture needle. Tract dilation will be performed up to 16-22 Fr, followed by the insertion of a suction-enabled miniaturized sheath (e.g., ClearPetra or equivalent). A mini-nephroscope will be introduced to visualize and fragment stones using Holmium:YAG fiber laser. Continuous irrigation combined with active negative-pressure suction through the access sheath will facilitate real-time removal of stone dust and fragments while maintaining low intrarenal pressure and clear visualization. A nephrostomy tube or double-J stent will be inserted at the surgeon's discretion.

05

What researchers measure

Primary outcomes

  1. stone-free rate (SFR) at 1 month postoperatively

    . SFR will be evaluated using a spiral non-contrast computed tomography (NCCT) scan performed at 1 month after the procedure. Stone-free status will be categorized as no residual or with residual fragments

    Time frame: 1 month postoperatively

06

Study locations

9 sites
  • Urology and nephrology center
    Al Mansurah, Outside U.S./Canada 35516, Egypt
  • Alexandria University
    Alexandria, Egypt
    • Amr Elgebaly · Contact
  • Assuit University
    Asyut, Egypt
  • Ain Shams University
    Cairo, Egypt
  • Cairo university
    Cairo, Egypt
    • Amr Elkady · Contact
  • Minya University
    Minya, Egypt
  • Menoufia University
    Shibīn al Kawm, Egypt
    • Mohamed Elshazly · Contact
  • Tanta University
    Tanta, Egypt
    • Maged Ragab · Contact
  • Zagazig university
    Zagazig, Egypt
07

Registry details

Key details

Study ID
NCT07295860
Lead sponsor
Mansoura University
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Dec 26, 2025

Study contacts

Mahmoud AN Laymon, A.Prof.
Contact
dr_mahmoudlaymon@mans.edu.eg
066053151
Ahmed Shokeir, Prof
Contact
ahmed.shokeir@hotmail.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion